Intracillin 1000 Milking Cow

Country: New Zealand

Language: English

Source: Ministry for Primary Industries

Active ingredient:

penicillin g procaine

Available from:

Virbac New Zealand Limited

INN (International Name):

penicillin g procaine

Composition:

penicillin g procaine 287 g/kg

Therapeutic area:

Antibiotic

Authorization status:

ACVM Registered

Authorization date:

1999-05-12

Summary of Product characteristics

Intracillin 1000 Milking Cow
Jul 2023
Syringe
VIRBAC
FOR ANIMAL TREATMENT ONLY
RVM
HIGHLY IMPORTANT ANTIBIOTIC
INTRACILLIN® 1000 MILKING COW
For the treatment of mastitis caused by Gram-positive organisms in
lactating dairy cows.
Each single-dose syringe contains 1000 mg of penicillin G procaine.
WITHHOLDING PERIODS
●
Milk:
TWICE
a
day milking – 96 hours (8 milkings).
●
Milk:
ONCE
a
day milking – 120 hours (5 once-a-day milkings).
●
Meat:
10 days
ACVM No. A7787.
Registered to and manufactured in New Zealand by VIRBAC NEW ZEALAND
LTD.
BATCH:
EXPIRY:
_Packaging item code _
_ _
_ _
_ _
Carton (top panel)
VIRBAC
FOR ANIMAL TREATMENT ONLY
RESTRICTED VETERINARY MEDICINE
HIGHLY IMPORTANT ANTIBIOTIC
INTRACILLIN® 1000 MILKING COW
For the treatment of mastitis caused by Gram-positive organisms in
lactating dairy cows.
Each single-dose syringe contains 1000 mg of procaine penicillin G
procaine.
●
Made in New Zealand
●
Proven in NZ conditions
●
Contains penicillin
Intracillin 1000 Milking Cow
Jul 2023
Contains 24 [or 21] syringes
Lactating cow logo
Carton (front panel)
VIRBAC
FOR ANIMAL TREATMENT ONLY
RESTRICTED VETERINARY MEDICINE
HIGHLY IMPORTANT ANTIBIOTIC
INTRACILLIN® 1000 MILKING COW
For the treatment of mastitis caused by Gram-positive organisms in
lactating dairy cows.
Each single-dose syringe contains 1000 mg of procaine penicillin G
procaine.
●
Made in New Zealand
●
Proven in NZ conditions
●
Contains penicillin
Contains 24 [or 21] syringes
Lactating cow logo
Carton (rear panel)
PENICILLIN G PROCAINE IS AN ANTIBIOTIC IN THE PENICILLIN FAMILY AND IS
CONSIDERED HIGHLY IMPORTANT TO
HUMAN AND ANIMAL HEALTH. The use of this antibiotic should only be for
the minimum period needed
to meet the clinical objective. Clinical response to this antibiotic
should be monitored during
treatment, and choice of therapy reviewed if clinical signs of disease
persist, increase, or relapse. In
the event of treatment failure, culture and sensitivity should be
considered to determine an
appropriate alternative therap